Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.

ABSTRACT: Most of the currently used cancer chemotherapies are based on compounds that inhibit general cellular mechanisms, such as DNA replication or tubulin function, and lack specificity in relation to features of the cancer cell. Recent advances in genomic studies have increased our knowledge of tumor cell biology, and a panoply of new targets have been postulated. This has provided an opportunity to develop and validate drugs that specifically target cancer cells through their unique genetic characteristics. Identification of MUC16/CA125 both as a marker and a driver of transformation led us to design a target-based high-content screen to identify and classify compounds that exhibit differential effect on MUC16-expressing cells. We developed a coculture assay in 384-well plate containing isogen

SUBMITTER: Rao TD 

PROVIDER: S-EPMC3191303 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature